WO2007101864A3 - Compounds that modulate ppar activity, their preparation and use - Google Patents
Compounds that modulate ppar activity, their preparation and use Download PDFInfo
- Publication number
- WO2007101864A3 WO2007101864A3 PCT/EP2007/052130 EP2007052130W WO2007101864A3 WO 2007101864 A3 WO2007101864 A3 WO 2007101864A3 EP 2007052130 W EP2007052130 W EP 2007052130W WO 2007101864 A3 WO2007101864 A3 WO 2007101864A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- preparation
- ppar activity
- modulate ppar
- modulate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Abstract
Compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPAR& and should be useful for treating conditions mediated by the same.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/282,244 US7943612B2 (en) | 2006-03-09 | 2007-03-07 | Compounds that modulate PPAR activity, their preparation and use |
CA002645719A CA2645719A1 (en) | 2006-03-09 | 2007-03-07 | Compounds that modulate ppar activity, their preparation and use |
EP07726688A EP1999098A2 (en) | 2006-03-09 | 2007-03-07 | Compounds that modulate ppar activity, their preparation and use |
JP2008557754A JP2009529512A (en) | 2006-03-09 | 2007-03-07 | Novel compounds, methods for their production and use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06110887.4 | 2006-03-09 | ||
EP06110887 | 2006-03-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007101864A2 WO2007101864A2 (en) | 2007-09-13 |
WO2007101864A3 true WO2007101864A3 (en) | 2007-10-25 |
Family
ID=36572326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/052130 WO2007101864A2 (en) | 2006-03-09 | 2007-03-07 | Compounds that modulate ppar activity, their preparation and use |
Country Status (5)
Country | Link |
---|---|
US (1) | US7943612B2 (en) |
EP (1) | EP1999098A2 (en) |
JP (1) | JP2009529512A (en) |
CA (1) | CA2645719A1 (en) |
WO (1) | WO2007101864A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943613B2 (en) | 2005-12-22 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE475642T1 (en) * | 2004-05-05 | 2010-08-15 | High Point Pharmaceuticals Llc | PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS |
EP1745014B1 (en) * | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
WO2005105726A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
EP2298742B1 (en) | 2005-06-30 | 2014-01-08 | High Point Pharmaceuticals, LLC | phenoxy acetic acids as PPAR delta activators |
CA2690229C (en) | 2007-06-29 | 2013-10-29 | Acucela, Inc. | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
MX2023001001A (en) | 2020-07-22 | 2023-03-01 | Reneo Pharmaceuticals Inc | Crystalline ppar-delta agonist. |
CN112759515B (en) * | 2020-12-28 | 2023-06-13 | 广东药科大学 | Novel FFA1 and PPAR alpha/gamma/delta quadruple agonist, preparation method thereof and application thereof as medicine |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997028115A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Antidiabetic agents |
US20040209936A1 (en) * | 2003-04-17 | 2004-10-21 | Bratton Larry D. | Compounds that modulate PPAR activity and methods of preparation |
US20050113440A1 (en) * | 2002-04-05 | 2005-05-26 | Auerbach Bruce J. | Compounds that modulate PPAR activity and methods for their preparation |
WO2005113506A1 (en) * | 2004-05-14 | 2005-12-01 | Irm Llc | Compounds and compositions as ppar modulators |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4920132A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
US5324743A (en) | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
GB2279659B (en) | 1993-07-05 | 1998-04-22 | Merck Patent Gmbh | Liquid crystalline material |
JP2002503203A (en) | 1996-02-02 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | Heterocyclic derivatives as antidiabetic and antiobesity agents |
AU719146B2 (en) | 1996-02-02 | 2000-05-04 | Merck & Co., Inc. | Antidiabetic agents |
AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
CA2244831A1 (en) | 1996-02-02 | 1997-08-07 | John T. Olson | Method of treating diabetes and related disease states |
ATE319440T1 (en) | 1996-12-23 | 2006-03-15 | Merck & Co Inc | ANTIDIABETIC AGENTS |
CA2295930C (en) | 1997-07-24 | 2010-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical compositions having cholesterol-lowering effect |
WO1999020275A1 (en) | 1997-10-17 | 1999-04-29 | Aventis Pharmaceuticals Products Inc. | Therapeutic uses of quinoline derivatives |
AR018698A1 (en) | 1999-06-01 | 2001-11-28 | Procter & Gamble | METHOD FOR THE TREATMENT OF LOSS OF HAIR WHICH IS INCLUDED TO MANAGE A COMPOSITION THAT INCLUDES A COMPOUND WHICH DOES NOT AFFECT THE HEART |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
AU7995300A (en) | 1999-10-05 | 2001-05-10 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
CN1423566A (en) | 1999-11-10 | 2003-06-11 | 武田药品工业株式会社 | Body weight gain inhibitor |
NZ517667A (en) | 1999-11-11 | 2004-05-28 | Lilly Co Eli | Oncolytic combinations for the treatment of cancer |
AU784722B2 (en) | 2000-02-18 | 2006-06-01 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
KR20020081424A (en) | 2000-03-09 | 2002-10-26 | 아벤티스 파마 도이칠란트 게엠베하 | Therapeutic uses of PPAR mediators |
US6448293B1 (en) | 2000-03-31 | 2002-09-10 | Pfizer Inc. | Diphenyl ether compounds useful in therapy |
JP2001354671A (en) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ACTIVATOR FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR delta |
AU2001277723A1 (en) | 2000-08-11 | 2002-02-25 | Nippon Chemiphar Co., Ltd. | Ppardelta activators |
US6630504B2 (en) | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
GB0024361D0 (en) | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
WO2002046154A1 (en) | 2000-12-05 | 2002-06-13 | Nippon Chemiphar Co., Ltd. | Peroxisome proliferator activated receptor d activators |
GB0031103D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
US7238716B2 (en) | 2000-12-28 | 2007-07-03 | Takeda Pharmaceuticals Company Limited | Alkanoic acid derivatives process for their production and use thereof |
EP1357914A2 (en) | 2001-02-02 | 2003-11-05 | SmithKline Beecham Corporation | Treatment of ppar mediated diseases |
WO2002076957A1 (en) | 2001-03-23 | 2002-10-03 | Nippon Chemiphar Co.,Ltd. | Activator for peroxisome proliferator-activated receptor |
WO2002079162A1 (en) | 2001-03-28 | 2002-10-10 | Eisai Co., Ltd. | Carboxylic acids |
JPWO2002080899A1 (en) | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | Gastrointestinal disease treatment |
TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
EP1394147A4 (en) | 2001-06-04 | 2007-10-24 | Eisai R&D Man Co Ltd | Carboxylic acid derivative and medicine comprising salt or ester of the same |
FR2826574B1 (en) | 2001-06-29 | 2005-08-26 | Oreal | COMPOSITIONS CONTAINING A HYDROXYDIPHENYL ETHER DERIVATIVE INHIBITING THE DEVELOPMENT OF BODY ODORS |
DK1424330T3 (en) | 2001-08-10 | 2012-01-16 | Nippon Chemiphar Co | Activator for peroxisome proliferator-responsive receptor delta |
EP1452521A4 (en) | 2001-08-17 | 2007-03-14 | Eisai R&D Man Co Ltd | Cyclic compound and ppar agonist |
CA2460313C (en) | 2001-09-14 | 2011-03-08 | Tularik Inc. | Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels |
EP1445258B1 (en) | 2001-10-12 | 2009-06-24 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-activated receptor delta |
WO2003033453A1 (en) * | 2001-10-17 | 2003-04-24 | Novo Nordisk A/S | Dicarboxylic acid derivatives, their preparation and therapeutical use |
DE10151390A1 (en) | 2001-10-18 | 2003-05-08 | Bayer Ag | acetic acid derivatives |
JP2003171275A (en) | 2001-12-11 | 2003-06-17 | Sumitomo Pharmaceut Co Ltd | Ppar delta agonist |
US7153878B2 (en) | 2002-02-25 | 2006-12-26 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
EP1480957A1 (en) | 2002-03-01 | 2004-12-01 | Smithkline Beecham Corporation | Hppars activators |
US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
US20030207924A1 (en) | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
DE10222034A1 (en) | 2002-05-17 | 2003-11-27 | Bayer Ag | New 2-benzenesulfonyl-3,4-dihydro-2(1H)-isoquinoline derivatives, are PPAR-delta activators useful e.g. for treating coronary heart disease, dyslipidemia or restenosis |
GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
GB0214254D0 (en) | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
DE10229777A1 (en) | 2002-07-03 | 2004-01-29 | Bayer Ag | Indoline-phenylsulfonamide derivatives |
WO2004007439A1 (en) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | Biaryl derivatives |
AU2003287912A1 (en) | 2002-12-20 | 2004-07-14 | Novo Nordisk A/S | Dicarboxylic acid derivatives as ppar-agonists |
US7816385B2 (en) | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
US7396850B2 (en) | 2003-01-06 | 2008-07-08 | Eli Lilly And Company | Pyrazole derivative as PPAR modulator |
DE10300099A1 (en) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Indole-phenylsulfonamide derivatives |
JP2006518738A (en) | 2003-02-12 | 2006-08-17 | トランス テック ファーマ,インコーポレイテッド | Substituted azole derivatives as therapeutic agents |
EP1597248B1 (en) | 2003-02-14 | 2007-12-26 | Eli Lilly And Company | Sulfonamide derivatives as ppar modulators |
US20070105959A1 (en) | 2003-03-11 | 2007-05-10 | Shinya Kusuda | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient |
TW200510279A (en) | 2003-03-13 | 2005-03-16 | Ono Pharmaceutical Co | Iminoether derivative compound and medicament containing same as active ingredient |
US20060258683A1 (en) | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
ATE339205T1 (en) | 2003-04-17 | 2006-10-15 | Kalypsys Inc | (3-Ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL PYRIMIDINE-2-YL)-AMINO)-PROPOXYÜ-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS |
CN1812978A (en) | 2003-04-30 | 2006-08-02 | 药物研发有限责任公司 | Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
ES2299906T3 (en) | 2003-11-25 | 2008-06-01 | Eli Lilly And Company | RECEIVER MODULATORS ACTIVATED BY PEROXISOM PROLIFERATORS. |
CN1956984B (en) | 2004-04-01 | 2010-06-09 | 安万特药物公司 | 1,3, 4-oxadiazol-2-ones as PPAR-Δ modulators |
CA2561159A1 (en) | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases |
DE602005027677D1 (en) | 2004-04-01 | 2011-06-09 | Aventis Pharma Inc | 1,3,4-OXADIAZOL-2-ONE AS PPAR DELTA MODULATORS AND ITS USE |
WO2005105726A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
EP2298742B1 (en) | 2005-06-30 | 2014-01-08 | High Point Pharmaceuticals, LLC | phenoxy acetic acids as PPAR delta activators |
-
2007
- 2007-03-07 EP EP07726688A patent/EP1999098A2/en not_active Withdrawn
- 2007-03-07 CA CA002645719A patent/CA2645719A1/en not_active Abandoned
- 2007-03-07 JP JP2008557754A patent/JP2009529512A/en not_active Withdrawn
- 2007-03-07 US US12/282,244 patent/US7943612B2/en not_active Expired - Fee Related
- 2007-03-07 WO PCT/EP2007/052130 patent/WO2007101864A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997028115A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Antidiabetic agents |
US20050113440A1 (en) * | 2002-04-05 | 2005-05-26 | Auerbach Bruce J. | Compounds that modulate PPAR activity and methods for their preparation |
US20040209936A1 (en) * | 2003-04-17 | 2004-10-21 | Bratton Larry D. | Compounds that modulate PPAR activity and methods of preparation |
WO2005113506A1 (en) * | 2004-05-14 | 2005-12-01 | Irm Llc | Compounds and compositions as ppar modulators |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943613B2 (en) | 2005-12-22 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
Also Published As
Publication number | Publication date |
---|---|
EP1999098A2 (en) | 2008-12-10 |
US20090048257A1 (en) | 2009-02-19 |
US7943612B2 (en) | 2011-05-17 |
WO2007101864A2 (en) | 2007-09-13 |
JP2009529512A (en) | 2009-08-20 |
CA2645719A1 (en) | 2007-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007101864A3 (en) | Compounds that modulate ppar activity, their preparation and use | |
TW200745004A (en) | Novel compounds, their preparation and use | |
UA95644C2 (en) | Pyridizinone derivative, pharmaceutical composition and treatment method | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
NO20092444L (en) | Heteroarylamidderivater | |
WO2011158042A3 (en) | Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections | |
WO2008135826A3 (en) | 2 -pyridine carboxamide derivatives as sodium channel modulators | |
TW200734306A (en) | Novel compounds, their preparation and use | |
WO2009156462A3 (en) | Organic compounds | |
EA201071089A1 (en) | HINAZOLIN DERIVATIVES AS RAF-KINASE MODULATORS AND METHODS FOR THEIR APPLICATION | |
WO2007109279A3 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
WO2008057856A3 (en) | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof | |
WO2007125103A3 (en) | Benzamide glucokinase activators | |
WO2010033977A3 (en) | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
WO2005086656A3 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
WO2008113559A3 (en) | Indolizines and aza-analog derivatives thereof as cns active compounds | |
TW200738659A (en) | Novel compounds | |
IL207976A0 (en) | Novel 02x7r antagonists and their use | |
WO2008013987A3 (en) | N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones | |
WO2006093547A3 (en) | Novel lipoxygenase inhibitors | |
WO2008049855A3 (en) | 7-azaindole derivatives as c-met kinase inhibitors | |
WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
WO2007076087A3 (en) | 3-aryl-substituted quinazolones, and uses thereof | |
WO2008061108A3 (en) | Phthalazine derivatives | |
WO2005112923A3 (en) | 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008557754 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2645719 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12282244 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007726688 Country of ref document: EP |